Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis Read more about Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis
EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19 Read more about EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19
Bristol Myers Squibb Announces New PDUFA Date for Mavacamten Read more about Bristol Myers Squibb Announces New PDUFA Date for Mavacamten
US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction Read more about US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction
AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial Read more about AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial
Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction Read more about Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19 Read more about AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19
US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction Read more about US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
Bayer’s KERENDIA® (finerenone) Receives U.S. FDA Approval for Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes Read more about Bayer’s KERENDIA® (finerenone) Receives U.S. FDA Approval for Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction Read more about Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction
